Omnicell (NASDAQ:OMCL) Updates FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 1.650-1.850 for the period, compared to the consensus estimate of 1.780. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $35.01 on Friday. The business has a 50 day moving average price of $39.01 and a two-hundred day moving average price of $42.58. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.75. The firm has a market cap of $1.64 billion, a PE ratio of 129.67, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Sell-side analysts expect that Omnicell will post 1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on OMCL shares. Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research report on Tuesday, February 4th. JPMorgan Chase & Co. reduced their price target on Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Monday, March 24th. Finally, Wells Fargo & Company decreased their target price on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Omnicell has a consensus rating of “Hold” and an average price target of $51.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.